Hunan Jiudian Pharmaceutical Co., Ltd.

XSEC:300705 Stock Report

Market Cap: CN¥12.0b

Hunan Jiudian Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Hunan Jiudian Pharmaceutical has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 26.7% per year. Hunan Jiudian Pharmaceutical's return on equity is 21.3%, and it has net margins of 17.2%.

Key information

39.6%

Earnings growth rate

38.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate26.7%
Return on equity21.3%
Net Margin17.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hunan Jiudian Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300705 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,9455081,373264
30 Jun 242,8414551,354277
31 Mar 242,7824171,415252
31 Dec 232,6933681,413254
30 Sep 232,6203711,380230
30 Jun 232,5133381,378208
31 Mar 232,3792911,298210
01 Jan 232,3262701,298201
30 Sep 222,0972431,149184
30 Jun 221,9272211,050174
31 Mar 221,799214991157
01 Jan 221,628204884146
30 Sep 211,451196791113
30 Jun 211,317162733103
31 Mar 211,09612260891
31 Dec 209788255182
30 Sep 209217250491
30 Jun 208915946498
31 Mar 2090652448110
31 Dec 1992455447110
30 Sep 199006540199
30 Jun 198677337685
31 Mar 198117035264
31 Dec 188017233657
30 Sep 187466731446
30 Jun 186807224947
31 Mar 186137120837
31 Dec 175356917029
30 Sep 174727213119
30 Jun 17430621430
31 Mar 17385561280
31 Dec 16376551270
30 Sep 16334391230
30 Jun 16320381190
31 Mar 16305411100
31 Dec 15290451010
30 Sep 1528143980
30 Jun 1527240950
31 Mar 1526941920
31 Dec 1426641890
31 Dec 1324136900

Quality Earnings: 300705 has high quality earnings.

Growing Profit Margin: 300705's current net profit margins (17.2%) are higher than last year (14.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300705's earnings have grown significantly by 39.6% per year over the past 5 years.

Accelerating Growth: 300705's earnings growth over the past year (36.8%) is below its 5-year average (39.6% per year).

Earnings vs Industry: 300705 earnings growth over the past year (36.8%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 300705's Return on Equity (21.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 02:03
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hunan Jiudian Pharmaceutical Co., Ltd. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Yizheng YangChina International Capital Corporation Limited
Kai WangCitic Securities Co., Ltd.